1. �����ѧҩѧ�뻯ѧѧԺ������ ���� 671000�� 2. �й������ž���ҽԺ�� a. ҩ��/��е�ٴ���������; b. �����ƣ����� 100853
Progress in Combination Therapy to Infection of Carbapenem-Resistant Pseudomonas aeruginosa
YANG De-qing1,2a, NI Wen-tao2b, JIANG Xue-wei2a, WANG Jin2a, WANG Rui2a, YU Bai-xue2a
1. School of Pharmacy and Chemistry, Dali University, Dali 671000, China; 2. Chinese People�� s Liberation Army General Hospital, a. Center of Medicine/Medical Devices Clinical Research; b. Department of Respiratory Diseases, Beijing 100853, China
Abstract��The outbreak of carbapenem-resistant Pseudomonas aeruginosa has been continuously reported in hospitals worldwide. The infection caused by carbapenem-resistant Pseudomonas aeruginosa increased the therapy failure and mortality, the effective antibiotics against carbapenem-resistant Pseudomonas aeruginosa are limited, and combination therapy is often recommended to treat CRPA infection. To fully master the advance on combination therapy of CRPA infection, and provide a theoretical basis for the rational use of the combination therapy, this article reviewed the synergistic effect in vitro or in vivo and clinical study of antimicrobial agents treating CRPA infection.
����࣬�����Σ���ѧά����誣�����ڰ�ѩ. ������ҩ������̼��ùϩͭ�̼ٵ�������Ⱦ���о���չ[J]. �й�ҩѧ��־, 2017, 52(14): 1208-1211.
YANG De-qing, NI Wen-tao, JIANG Xue-wei, WANG Jin, WANG Rui, YU Bai-xue. Progress in Combination Therapy to Infection of Carbapenem-Resistant Pseudomonas aeruginosa. Chinese Pharmaceutical Journal, 2017, 52(14): 1208-1211.
MORALES E, COTS F, SALA M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res, 2012, 12(1): 122.
[2]
RAI S, DAS D, NIRANJAN D K, et al. Carriage prevalence of carbapenem-resistant Enterobacteriaceae in stool samples: a surveillance study. Australas Med J, 2014, 7(2): 64-67.
[3]
LESHO E, CHUKWUMA U, SPARKS M, et al. Anatomic, geographic, and taxon-specific relative risks of carbapenem resistance in the Health Care System of the US. Department of Defense. J Clin Microbiol,2016, 54(6):1546-1551.
[4]
RODLOFF A C, DOWZICKY M J. Antimicrobial susceptibility among european gram-negative and gram-positive isolates collected as part of the tigecycline evaluation and surveillance trial(2004-2014) . Chemotherapy, 2016, 62(1):1-11.
[5]
LABARCA J A, SALLES M J, SEAS C, et al. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America . Crit Rev Microbiol, 2016, 42(2): 276-292.
[6]
KIRATISIN P, CHONGTHALEONG A, TAN T Y, et al. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study . Int J Antimicrob Agents, 2012, 39(4): 311-316.
[7]
Committee of Experts on Rational Drug Use, National Health and Family Planning Commission of the P.R.China; China Antimicrobial Resistance Surveillance System Surveillance Report of bacterial resistance in 2015. Chin Lic Pharm(�й�ִҵҩʦ), 2016, 13(3): 3-8.
[8]
CORNAGLIA G, MAZZARIOL A, LAURETTI L, et al. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-betalactamase . Clin Infect Dis, 2000, 31(5): 1119-1125.
[9]
TSAKRIS A, POURNARAS S, WOODFORD N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece . J Clin Microbiol, 2000, 38(3): 1290-1292. HUH K, KIM J, CHO S Y, et al. Continuous increase of the antimicrobial resistance among gram-negative pathogens ausing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases(KONSID) . Diagn Microbiol Infect Dis, 2013,76(4):477-482. YAHA D, FARBMAN L, LEIBOVICI L, et al. Colistin: new lessons on an old antibiotic . Clin Microbiol Infect, 2012,18(1):18-29. RAO G G, LY N S, HAAS C E, et al. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease . Antimicrob Agents Chemother, 2014,58(3):1381-1388. National Health and Family Planning Commission of the P.R. China. Resistant Gram-Negative Bacteria Infection Diagnostic Manual(��ҩ�������Ծ���Ⱦ�����ֲ�). Vol 1. Beijing:People��s Medical Publishing House Press, 2015:20. DI X, WANG R, LIU B, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa . J Antibiot(Tokyo), 2015, 68(9):551-555. LOPEZ-FABAL F, CULEBRAS E, BONILLA I, et al. In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit. Rev Esp Quimioter, 2008, 21(3):189-193. AOKI N, TATEDA K, KIKUCHI Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa . J Antimicrob Chemother,2009, 63(3):534-542. NIU H, LIANG B B, ZHANG X, et al. In vitro activity of colistin combination with biapenem against carbopenems-resistant Pseudomonas aeruginosa . Chin J Clin Pharm (�й��ٴ�ҩ��ѧ��־), 2015, 31(24): 2437-2439. HU Y F,LIU C P,WANG N Y, et al.In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem againstmultidrug-resistant clinical isolates of Pseudomonas aeruginosa. BMC Infect Dis, 2016,16(1):444. NAGAOKA R, IKAWA K, ONODERA M,et al. In vitro combined effects of double antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa isolates: comparison among combinations of colistin, arbekacin, aztreonam, rifampicin and piperacillin . Jpn J Antibiot, 2014,67(3):167-174. YE M, YANG X M,WANG G, et al. The analysis of zymogenic state against Carbapenems-resistant Pseudomonas aeruginosa using a susceptibility test . Mili Med J South Chin(���Ϲ���ҽҩ), 2011, 13(2): 135-137. IGBINOSA E O, ODJADJARE E E, IGBINOSA I H, et al. Antibiotic synergy interaction against multidrug-resistant Pseudomonas aeruginosa isolated from an abattoireffluent environment. Scien World J, 2012, 2012(5):308034. SANTOS D A, NASCIMENTO M M, VITALI L H, et al. In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa . Rev Soc Bras Med Trop,2013,6(3):299-303. PENG J Q, ZENG C J, LI G N, et al. Evaluation of combined effects of ceforperzazone/sulbactaman amikamcin againsts trains of imipenem-resistant Pseudomonas aeruginosa. Int J Lab Med(���ʼ���ҽѧ��־), 2015, 36(13): 1902-1904. XU Y P, CAO J R, LI L Z, et al. Combination antimicrobial susceptibility test on 43 multi-drug-resistant isolates of Pseudomonas aeruginosa . Chin J Nosocomiol(�л�ҽԺ��Ⱦѧ��־), 2007, 17(2): 210-212. KUNAKONVICHAYA B, THIRAPANMETHEE K, KHUNTAYAPORN P, et al. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents, 2015, 45(5): 556-557. HE W, KANIGA K, LYNCH A S, et al. In vitro E-test synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the E-test method . Diagn Microbiol Infect Dis, 2012, 74(4): 417-419. LEE H, ROH K H, HONG S G, et al. In vitro synergistic effects of antimicrobial combinations on extensively drug-resistant pseudomonasaeruginosa and Acinetobacter baumannii isolates . Ann Lab Med, 2016,6(2):138-144. ERDEM I, KAYNAR-TASCIOGLU J, KAYA B, et al. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacinagainst multidrug-resistant Pseudomonaseruginosa strains . Int J Antimicrob Agents, 2015, 45(5):556-557. KUNAKONVICHAYA B, THIRAPANMETHEE K, KHUNTAYAPORN P, et al. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates . Int J Antimicrob Agents, 2015, 45(5):556-557. GOMEZ-GARCES J L, GIL-ROMERO Y, SANZ-RODRIGUEZ N, et al. In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa . EnfermInfecc Microbiol Clin, 2016, 34(4): 228-231. XIONG Y Q, POTEL G, CAILLON J, et al. Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimentalendocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa . Antimicrob Agents Chemother, 1995,39(2):496-496. KANELLAKOPOULOU K, SARAFIS P, GALANI I,et al. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa . Int J Antimicrob Agents, 2008, 32(1):33-39. ERENM I, KUCUKERCAN M, CERAN N. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam,or meropenem with ciprofloxacinagainst multidrug-resistant Pseudomonas aeruginosa strains . Chemotherapy, 2003, 49(6):294-297. WEN Y K, CAO M, ZHOU, et al.Combined drug sensitivity test of carbapenem-resistant Pseudomonasaeruginosa in vitro . Chin J Antibiot(�й���������־), 2012, 37(7):536-538. DI X Z, BAI N, TANG M J, et al. Combined effect of fosfomycin and polymyxin E against carbapenem-Pseudomonas aeruginosa. Chinese Pharmaceutical Association Drug Clinical Evaluation ResearchSpecialized Committee, 2015. GAN X D. Clinical efficacy of Azithromycin combined with ciprofloxacin in the treatment of Pseudomonas aeruginosa infection in patients with Pseudomonas aeruginosa . Chin J Clin Rational Drug Use(�ٴ�������ҩ), 2014, 7(6): 57-58. XIA C, XIE X H, WANG L L, et al. Effects of azithromycin on MexAb-OprM efflux pump and antibiotic resistance in Pseudomonas aeruginosa infection . J Huazhong Univ Sci Technol(���пƼ���ѧѧ��), 2012, 10(3) : 69-75. ZHANG X C, QIN Y F, BAO C M, et al. Azithromycin combined with ciprofloxacin in treament of carbarpenem-resistant Pseudomonas aeruginosainfection . Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2013, 33(16): 1341-1343. LIU Q M, ZHANG Z, LIAO H. Clinical studies of ciprofloxacin and azithromycin for trentment of carbapenem-resistant Pseudomonas aeruginosa infection . Chin J Med Guide(�й�ҽҩ����), 2015, 17(6): 591-593. HOFFMAN N, LEE B, HENTZER M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother, 2007, 51(10): 3677-3687. JIAN L J. Intervention effect and mechanism of azithromycin on the biofilm and virulence factors of Pseudomonas aeruginosa . Nanning: Guangxi Medical University, 2011. LIANG T, LIU L, SUN Z Y. Analysis of clinical efficacy of combining use of azithromycin and ciprofloxacin to cure carbapenem resistant Pseudomonas aeruginosa infections . Chin J Nosocomiol(�л�ҽԺ��Ⱦѧ��־), 2014, 24(11): 2680-2683. WANG L M,YAO M, HAN M, et al. Management of Carbapenem-resistant Pseudomonas Aeruginosa-induced Infection. Chinese Pharmaceutical Association:China Pharmaceutical Conference and the thirteenth Chinese pharmacist week proceedings, Beijing:2013:2601-2607. APISARNTHANARAK A, MUNDY L M. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitoryconcentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin . Int J Antimicrob Agents, 2012, 39(3): 271-272. CHEN Y F, CAO W S. Review on the clinical safety of etimicin sulfate . Chin J Pharm Eco(�й�ҩ�ﾭ��ѧ), 2012,(6): 41-44.
2017, Vol. 52 
